美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

MapLight Therapeutics, Inc.

11.36

+0.15001.34%

成交量：56.35萬

成交額：631.32萬

市值：5.27億

市盈率：-2.25

高：11.44

開：11.21

低：10.51

收：11.21

52周最高：40.43

52周最低：9.10

股本：4,637.78萬

流通股本：1,340.27萬

量比：0.92

換手率：4.20%

股息：- -

股息率：- -

每股收益(TTM):-5.0580

每股收益(LYR):-18.5643

淨資產收益率：-111.55%

總資產收益率：-67.11%

市淨率：1.51

市盈率(LYR):-0.61

資料載入中...

總覽公司新聞資訊公告

美國研究綜述-BioLife Solutions、Gossamer Bio、Intuit

MapLight精神分裂症藥物未能通過每日一次給藥測試，股價暴跌

MapLight Therapeutics 盤前暴跌55.7%：精神分裂症藥物中期試驗結果不及預期

MapLight Therapeutics 每日一次330/6毫克劑量未能達到主要終點統計顯著性

MapLight Therapeutics在2期試驗中：210/3毫克BID劑量於第5周顯著改善PANSS評分

MapLight Therapeutics 公布精神分裂症藥物 Ml-007C-Ma 二期 Zephyr 試驗積極頂線結果

Maplight Therapeutics旗下Ml-007C-Ma耐受性良好，無嚴重或藥物相關嚴重不良事件

MapLight Therapeutics——推進額外註冊性試驗，與FDA啓動二期尾聲溝通

美國研究綜述-德克爾斯品牌、羅林斯、聯合租賃

Raymond James首予MapLight Therapeutics強力買入評級，目標價46美元

BUZZ-美股行情——蓋蒂圖片社、Ecarx、Maplight Therapeutics

BUZZ-Maplight Therapeutics股價上漲，因其自閉症藥物在特定亞組中顯示出療效，儘管臨床試驗未達預期

MapLight Therapeutics公司Ml-004在二期IRIS試驗中總體耐受性良好，未出現嚴重或重度不良事件

MapLight Therapeutics, Inc.聲明：Setia離職無權獲得任何遣散費

MapLight Therapeutics首席財務官Vishwas Setia於2026年6月18日起即刻離職 - 美國證券交易委員會文件披露

MapLight Therapeutics宣佈Zephyr二期臨床試驗完成入組並更新關鍵結果預期時間表

BUZZ--美國股票走勢-達美、GATX、Humana

BUZZ-尼德姆首次覆蓋MapLight，看好精神分裂症藥物潛力

Maplight Therapeutics, Inc.盤中異動股價大漲5.11%報18.50美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/MPLT/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MPLT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":11.36,"timestamp":1787601600000,"preClose":11.21,"halted":0,"volume":563455,"delay":0,"changeRate":0.0133809099018732,"floatShares":13402700,"shares":46377800,"eps":-5.058,"marketStatus":"盤前交易","change":0.15,"latestTime":"08-25 04:03:48 EDT","open":11.21,"high":11.44,"low":10.51,"amount":6313184.780735,"amplitude":0.082962,"askPrice":12.25,"askSize":1,"bidPrice":11.25,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-5.058,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1787664600000},"marketStatusCode":1,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":11.36,"postHourTrading":{"tag":"盘后","latestPrice":11.38,"preClose":11.36,"latestTime":"19:30 EDT","volume":4806,"amount":54611.07,"timestamp":1787614207201,"change":0.02,"changeRate":0.001761,"amplitude":0.004401},"volumeRatio":0.922014,"impliedVol":1.1393,"impliedVolPercentile":0.35},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","floatShares":13402700,"roa":"-67.11%","roe":"-111.55%","lyrEps":-18.564313,"volumeRatio":0.922014,"shares":46377800,"dividePrice":0,"high":11.44,"amplitude":0.082962,"preClose":11.21,"low":10.51,"week52Low":9.1,"pbRate":"1.51","week52High":40.43,"institutionHeld":0,"latestPrice":11.36,"eps":-5.058,"divideRate":0,"volume":563455,"delay":0,"ttmEps":-5.058,"open":11.21,"prevYearClose":17.565,"prevWeekClose":11.21,"prevMonthClose":13.02,"prevQuarterClose":35.84,"fiveDayClose":11.245,"twentyDayClose":9.905,"sixtyDayClose":29.78},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MPLT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"MPLT","fiscalQuarterEnding":"2026/06","expectedEps":-1.4,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-05-14","symbol":"MPLT","fiscalQuarterEnding":"2026/03","expectedEps":-0.91,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-1.34},{"market":"US","date":"2026-03-26","symbol":"MPLT","fiscalQuarterEnding":"2025/12","expectedEps":-1.05,"name":null,"time":"盤前","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"pre","actualEps":-2.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MPLT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MPLT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3571,"buy":0.5,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":14,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MPLT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MPLT","date":"2026-08-21","current":-2.245947,"percent":0.995098,"low":-9.047313,"twenty":-8.09314,"median":-7.454432,"eighty":-6.435493,"high":-2.251599,"avg":-7.006373,"sd":1.578045,"marketCap":520823053},"quantilePoints":[{"date":"2025-10-31","current":-8.673514,"twenty":-8.310978,"median":-7.61973,"eighty":-7.489746,"marketCap":801692922},{"date":"2025-11-07","current":-7.620605,"twenty":-8.035178,"median":-7.644213,"eighty":-7.545137,"marketCap":704372551},{"date":"2025-11-14","current":-6.742394,"twenty":-7.98511,"median":-7.554503,"eighty":-7.23627,"marketCap":623199506},{"date":"2025-11-21","current":-6.274959,"twenty":-7.73109,"median":-7.394197,"eighty":-6.810384,"marketCap":579994498},{"date":"2025-11-28","current":-6.435493,"twenty":-7.639491,"median":-7.190943,"eighty":-6.54881,"marketCap":594832581},{"date":"2025-12-05","current":-7.783335,"twenty":-7.714027,"median":-7.115398,"eighty":-6.435493,"marketCap":800383679},{"date":"2025-12-12","current":-8.528142,"twenty":-7.986054,"median":-7.394197,"eighty":-6.45249,"marketCap":876974375},{"date":"2025-12-19","current":-8.462361,"twenty":-8.266224,"median":-7.554503,"eighty":-6.54881,"marketCap":870209954},{"date":"2025-12-26","current":-7.689969,"twenty":-8.289163,"median":-7.620605,"eighty":-6.624355,"marketCap":790782566},{"date":"2026-01-02","current":-7.454432,"twenty":-8.20424,"median":-7.61973,"eighty":-6.670627,"marketCap":766561577},{"date":"2026-01-09","current":-7.295285,"twenty":-8.111814,"median":-7.53948,"eighty":-6.75706,"marketCap":750196044},{"date":"2026-01-16","current":-7.84275,"twenty":-8.074467,"median":-7.609335,"eighty":-6.818055,"marketCap":806493478},{"date":"2026-01-23","current":-7.885189,"twenty":-7.999774,"median":-7.554503,"eighty":-6.827382,"marketCap":810857620},{"date":"2026-01-30","current":-7.885189,"twenty":-8.004018,"median":-7.620167,"eighty":-6.893484,"marketCap":810857620},{"date":"2026-02-06","current":-6.662942,"twenty":-7.999774,"median":-7.609335,"eighty":-6.893484,"marketCap":685170325},{"date":"2026-02-13","current":-7.308017,"twenty":-7.988887,"median":-7.547968,"eighty":-7.020967,"marketCap":751505286},{"date":"2026-02-20","current":-7.605091,"twenty":-7.988887,"median":-7.532944,"eighty":-7.096512,"marketCap":782054282},{"date":"2026-02-27","current":-7.392895,"twenty":-7.98511,"median":-7.541432,"eighty":-7.116712,"marketCap":760233571},{"date":"2026-03-06","current":-7.622066,"twenty":-7.966096,"median":-7.547968,"eighty":-7.127226,"marketCap":783799939},{"date":"2026-03-13","current":-8.122848,"twenty":-7.991064,"median":-7.592359,"eighty":-7.180699,"marketCap":835296817},{"date":"2026-03-20","current":-7.422602,"twenty":-8.000623,"median":-7.590237,"eighty":-7.203617,"marketCap":763288470},{"date":"2026-03-27","current":-5.207658,"twenty":-7.991064,"median":-7.583871,"eighty":-7.203617,"marketCap":839224545},{"date":"2026-04-02","current":-5.640953,"twenty":-7.988887,"median":-7.541432,"eighty":-7.116384,"marketCap":909050820},{"date":"2026-04-10","current":-7.964495,"twenty":-7.986054,"median":-7.516065,"eighty":-6.867043,"marketCap":1283494221},{"date":"2026-04-17","current":-7.720766,"twenty":-7.972363,"median":-7.507481,"eighty":-6.969974,"marketCap":1244216941},{"date":"2026-04-24","current":-7.883252,"twenty":-7.986054,"median":-7.516065,"eighty":-7.077626,"marketCap":1270401794},{"date":"2026-05-01","current":-8.966125,"twenty":-8.009111,"median":-7.554503,"eighty":-7.116384,"marketCap":1444908993},{"date":"2026-05-08","current":-8.214962,"twenty":-8.052399,"median":-7.590237,"eighty":-7.121808,"marketCap":1323857628},{"date":"2026-05-15","current":-6.658186,"twenty":-8.072823,"median":-7.605091,"eighty":-7.121808,"marketCap":1328174850},{"date":"2026-05-22","current":-6.655912,"twenty":-8.056678,"median":-7.585993,"eighty":-6.867043,"marketCap":1327721393},{"date":"2026-05-29","current":-6.769572,"twenty":-8.053247,"median":-7.547968,"eighty":-6.753265,"marketCap":1350394231},{"date":"2026-06-05","current":-6.842314,"twenty":-8.050011,"median":-7.507675,"eighty":-6.705014,"marketCap":1364904847},{"date":"2026-06-12","current":-6.899144,"twenty":-8.036085,"median":-7.484139,"eighty":-6.662816,"marketCap":1376241266},{"date":"2026-06-18","current":-6.64,"twenty":-8.014204,"median":-7.474515,"eighty":-6.654094,"marketCap":1324547195},{"date":"2026-06-26","current":-7.265128,"twenty":-8.003169,"median":-7.454432,"eighty":-6.652876,"marketCap":1449247804},{"date":"2026-07-02","current":-8.201684,"twenty":-8.01675,"median":-7.469285,"eighty":-6.653639,"marketCap":1636071990},{"date":"2026-07-10","current":-9.047313,"twenty":-8.054945,"median":-7.484139,"eighty":-6.655912,"marketCap":1804757904},{"date":"2026-07-17","current":-8.460828,"twenty":-8.122848,"median":-7.507675,"eighty":-6.658186,"marketCap":1687766060},{"date":"2026-07-24","current":-8.008463,"twenty":-8.137812,"median":-7.547968,"eighty":-6.662732,"marketCap":1597528165},{"date":"2026-07-31","current":-3.189291,"twenty":-8.129236,"median":-7.516065,"eighty":-6.653448,"marketCap":636199834},{"date":"2026-08-07","current":-3.018802,"twenty":-8.123697,"median":-7.486261,"eighty":-6.561799,"marketCap":602190577},{"date":"2026-08-14","current":-2.692276,"twenty":-8.099082,"median":-7.474515,"eighty":-6.526795,"marketCap":537055294},{"date":"2026-08-21","current":-2.266153,"twenty":-8.09314,"median":-7.454432,"eighty":-6.435493,"marketCap":520823053}],"updateTime":1787645028910},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MPLT\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654507116","title":"美國研究綜述-BioLife Solutions、Gossamer Bio、Intuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2654507116","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654507116?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 15:33","pubTimestamp":1785224018,"startTime":"0","endTime":"0","summary":"美国研究综述-BioLife Solutions、Gossamer Bio、Intuit路透7月28日-周五，华尔街证券分析师修订了多家在美国上市公司的评级和目标股价，其中包括BioLife Solutions、Gossamer Bio和Intuit。股票按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nL4T43U0KC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBOE","MPLT","PINE","W","MSBI","INTU","PKG","FMBH","RIOT","IP","CHRW","HUT","SRCE","WULF","FRPT","THC","AGYS","CIFR","VIRT","GSHD","GOSS","NEE","BWFG","OWL","MNSH","CDNS","HAPN","HCA","HTH","SSB","NVTS","SHBI","ENSG","CLSK","HIG","DGX","HRB","BY","OTIS","CHMG","FFIV","BLFS","GTY","PCOR","LMT","TSLA","LW","NEM","HBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654506010","title":"MapLight精神分裂症藥物未能通過每日一次給藥測試，股價暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2654506010","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654506010?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 20:28","pubTimestamp":1785155285,"startTime":"0","endTime":"0","summary":"MapLight精神分裂症药物未能通过每日一次给药测试，股价暴跌路透7月27日-MapLight Therapeutics周一表示，其精神分裂症药物在中期临床试验的每日一次给药组中，未能显示出具有统计学意义的症状改善，导致其股价在盘前交易中暴跌55%。MapLight指出，该药总体耐受性良好，未报告任何严重或与治疗相关的严重副作用。MapLight 还正在研究该药物对阿尔茨海默病伴发精神病的疗效，初步结果预计将于 2027 年下半年公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4T43T0YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670711123.USD","LU1670710588.SGD","BMY","IE00BJT1NW94.SGD","LU0225771236.USD","BK4581","LU0432979614.USD","IE00B2B36J28.USD","BK4559","LU1291159041.SGD","LU1718418525.SGD","FTXH","BK4007","LU0321505868.SGD","LU1585245621.USD","LU1670711040.USD","IE0002141913.USD","BK4534","LU1430594728.SGD","LU1868836757.USD","MPLT","LU1571399168.USD","IE00BJJMRZ35.SGD","LU0456855351.SGD","LU1868836591.USD","BK4588","LU2133065610.SGD","LU2125154778.USD","LU1868836914.USD","IHE","LU1983299246.USD","LU1032466523.USD","BK4139","LU0306806265.USD","IE00BFXG1179.USD","LU2596442595.SGD","IE00BSNM7G36.USD","LU1868837300.USD","LU1093756325.SGD","BK4532","LU1093756168.USD","LU1323610961.USD","IE00BFTCPJ56.SGD","LU1883839398.USD","BK4585","LU0985481810.HKD","LU0225284248.USD","LU2360032135.SGD","LU1989771016.USD","LU0306807586.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114412720","title":"MapLight Therapeutics 盤前暴跌55.7%：精神分裂症藥物中期試驗結果不及預期","url":"https://stock-news.laohu8.com/highlight/detail?id=1114412720","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114412720?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 20:13","pubTimestamp":1785154388,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics 的股价在盘前交易中遭遇重挫，跌幅高达55.7%。这一剧烈波动源于公司公布了其针对精神分裂症药物的中期试验结果。市场对此次披露的数据反应极为负面，投资者信心受挫，导致股价在开盘前便大幅跳水。该公司正面临严峻考验，后续发展引人关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109776896","title":"MapLight Therapeutics 每日一次330/6毫克劑量未能達到主要終點統計顯著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1109776896","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109776896?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 19:18","pubTimestamp":1785151139,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics Inc. 宣布，其每日一次（QD）330/6毫克剂量的治疗方案，在主要终点指标上未能实现统计学显著性。这一结果意味着该剂量方案在该项研究中并未展现出预期的疗效优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137673591","title":"MapLight Therapeutics在2期試驗中：210/3毫克BID劑量於第5周顯著改善PANSS評分","url":"https://stock-news.laohu8.com/highlight/detail?id=1137673591","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137673591?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 19:03","pubTimestamp":1785150236,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics的研究取得新进展。其210/3毫克BID剂量的药物，在2期临床试验中，展现出显著成效。该试验在第5周时，患者的PANSS评分获得了明显改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154497493","title":"MapLight Therapeutics 公布精神分裂症藥物 Ml-007C-Ma 二期 Zephyr 試驗積極頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1154497493","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154497493?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 19:02","pubTimestamp":1785150160,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics 宣布，其针对精神分裂症的在研药物 Ml-007C-Ma，在二期 Zephyr 临床试验中取得了积极的顶线结果。这一里程碑式的进展，为饱受精神分裂症困扰的患者群体带来了新的希望。该研究的详细数据，将在后续的医学会议上进一步公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193604406","title":"Maplight Therapeutics旗下Ml-007C-Ma耐受性良好，無嚴重或藥物相關嚴重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1193604406","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193604406?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 19:02","pubTimestamp":1785150133,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics, Inc. 宣布，其研发的Ml-007C-Ma在临床试验中展现出良好的耐受性。值得注意的是，该药物在受试者中未引发任何严重不良事件，亦未出现与药物相关的严重不良反应。这一结果，无疑为后续的研发工作注入了强心剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100562159","title":"MapLight Therapeutics——推進額外註冊性試驗，與FDA啓動二期尾聲溝通","url":"https://stock-news.laohu8.com/highlight/detail?id=1100562159","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100562159?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 19:02","pubTimestamp":1785150132,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics——计划启动一项额外的注册性试验，并在二期临床结束时与美国食品药品监督管理局（FDA）展开对接。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653704896","title":"美國研究綜述-德克爾斯品牌、羅林斯、聯合租賃","url":"https://stock-news.laohu8.com/highlight/detail?id=2653704896","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653704896?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 15:16","pubTimestamp":1784877371,"startTime":"0","endTime":"0","summary":"美国研究综述-德克尔斯品牌、罗林斯、联合租赁路透7月24日-周五，华尔街证券分析师修订了多家在美国上市公司的评级和目标价，其中包括德克斯品牌、罗林斯和联合租赁。股票按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL4S43Q0I8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMDL","EW","BPOP","ALK","FOA","MBWM","ROL","DAMD","KRMN","MOH","TEK","SAM","DFTX","PNFP","NSC","THRM","DECK","LOB","MEDP","AMP","FCXG","CMCSA","BMED","JUP.UK","ACI","HON","FCX","URI","AAL","CNAV","BX","CTSH","IDEF","LMT","DOV","DOW","AMD","NVR","AMAT","FCNCA","DOMO","NDAQ","NIC","OBK","PSCH","PKG","MPLT","R","LRCX","INTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105042736","title":"Raymond James首予MapLight Therapeutics強力買入評級，目標價46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105042736","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105042736?lang=zh_tw&edition=fundamental","pubTime":"2026-06-25 19:20","pubTimestamp":1782386432,"startTime":"0","endTime":"0","summary":"Raymond James 分析师近日发布研报，首次覆盖生物技术公司 MapLight Therapeutics，并给予其“强力买入”评级。报告同时为该股设定了46美元的目标价，显示出对该司未来前景的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645951076","title":"BUZZ-美股行情——蓋蒂圖片社、Ecarx、Maplight Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2645951076","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645951076?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 23:57","pubTimestamp":1782143820,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4S42U1CS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4124","BK4077","BK4139","MPLT","ECX","GETY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645073042","title":"BUZZ-Maplight Therapeutics股價上漲，因其自閉症藥物在特定亞組中顯示出療效，儘管臨床試驗未達預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2645073042","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645073042?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 22:53","pubTimestamp":1782140023,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4S42U19B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130988345","title":"MapLight Therapeutics公司Ml-004在二期IRIS試驗中總體耐受性良好，未出現嚴重或重度不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1130988345","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130988345?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 19:04","pubTimestamp":1782126257,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics公司宣布，其候选药物Ml-004在二期IRIS临床试验中表现出良好的安全性特征。试验数据显示，该药物总体耐受性良好，期间未报告任何严重或重度的不良事件。\n这一积极的安全数据为Ml-004的进一步开发奠定了重要基础。公司将继续推进相关临床研究，以评估该疗法在目标适应症中的有效性与长期安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135687202","title":"MapLight Therapeutics, Inc.聲明：Setia離職無權獲得任何遣散費","url":"https://stock-news.laohu8.com/highlight/detail?id=1135687202","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135687202?lang=zh_tw&edition=fundamental","pubTime":"2026-06-19 05:07","pubTimestamp":1781816835,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics, Inc.发布声明称，根据相关协议条款，Setia先生因其离职行为，无权获得任何形式的遣散费用。公司强调，此举严格遵循了既定的雇佣合同与内部政策规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156015941","title":"MapLight Therapeutics首席財務官Vishwas Setia於2026年6月18日起即刻離職 - 美國證券交易委員會文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1156015941","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156015941?lang=zh_tw&edition=fundamental","pubTime":"2026-06-19 05:03","pubTimestamp":1781816596,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会(SEC)的文件，生物制药公司MapLight Therapeutics, Inc.宣布，其首席财务官Vishwas Setia已于2026年6月18日即刻卸任。\n该文件显示，Setia的离职自2026年6月18日起立即生效。目前，公司尚未公布其首席财务官职位的继任计划。此次人事变动通过SEC的正式文件对外披露，标志着公司管理层的一次重要调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126953001","title":"MapLight Therapeutics宣佈Zephyr二期臨床試驗完成入組並更新關鍵結果預期時間表","url":"https://stock-news.laohu8.com/highlight/detail?id=1126953001","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126953001?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 19:00","pubTimestamp":1777633228,"startTime":"0","endTime":"0","summary":"生物制药公司MapLight Therapeutics近日宣布，其针对精神神经疾病的Zephyr二期临床试验已完成患者入组工作。该公司同时更新了这项研究的关键顶线结果预计公布时间。\n此次临床试验的顺利推进标志着MapLight Therapeutics在精神神经疾病治疗领域取得重要进展。公司表示将按计划推进后续数据整理与分析工作，并及时向市场披露相关研究成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625945239","title":"BUZZ--美國股票走勢-達美、GATX、Humana","url":"https://stock-news.laohu8.com/highlight/detail?id=2625945239","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625945239?lang=zh_tw&edition=fundamental","pubTime":"2026-04-08 19:45","pubTimestamp":1775648732,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nL4S40R11B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEHR","COIN","CVX","ABT","UAL","KKR","BTAI","MSTP","OWL","ZTS","ANIP","ELAN","IDXX","OXY","CDE","LUV","GEMI","DE","CLSK","HL","MSTR","COIW","CF","LEVI","FCX","HUM","BKNG","BX","EXPE","INSM","DVN","NVAX","VSAT","AAL","GATX","IBIO","MOS","FIAT","COIG","AMGN","CCL","MPLT","XOM","DAL","BAC","APO","NCLH","SCCO","NEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625943995","title":"BUZZ-尼德姆首次覆蓋MapLight，看好精神分裂症藥物潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=2625943995","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625943995?lang=zh_tw&edition=fundamental","pubTime":"2026-04-08 19:11","pubTimestamp":1775646704,"startTime":"0","endTime":"0","summary":"BUZZ-尼德姆首次覆盖MapLight，看好精神分裂症药物潜力4月8日 - ** Needham给予Maplight Therapeutics MPLT.O\"买入 \"评级，目标价37美元。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nL4S40R0Z4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","LU0225771236.USD","BK4559","IE00BSNM7G36.USD","IE0009355771.USD","LU1718418525.SGD","BK4139","BK4007","LU1291159041.SGD","LU1323610961.USD","IE00BJT1NW94.SGD","LU1430594728.SGD","LU0061475181.USD","LU2242646821.SGD","LU1868837300.USD","MPLT","LU1261432733.SGD","LU0868494617.USD","LU1670711040.USD","LU0306807586.USD","LU1868836914.USD","LU2360032135.SGD","LU1093756168.USD","BMY","LU1670710588.SGD","LU0267386448.USD","LU2242652126.USD","LU2133065610.SGD","IE00B2B36J28.USD","LU0225284248.USD","BK4534","LU1093756325.SGD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00BFXG1179.USD","LU0237698245.USD","LU1883839398.USD","LU0114720955.EUR","LU1571399168.USD","LU1670710661.SGD","LU0321505439.SGD","LU1868837136.USD","LU2125154935.USD","LU1074936037.SGD","LU2125154778.USD","LU0321505868.SGD","BK4585","LU1983299246.USD","LU1868836757.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617552908","title":"Maplight Therapeutics, Inc.盤中異動 股價大漲5.11%報18.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617552908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617552908?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 03:41","pubTimestamp":1772566875,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日03时41分，Maplight Therapeutics, Inc.股票出现波动，股价急速拉升5.11%。截至发稿，该股报18.50美元/股，成交量7.8101万股，换手率0.17%，振幅7.81%。Maplight Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.80%。其相关个股中，Edesa Biotech, Inc.、Onconetix, Inc.、Hcw Biologics Inc.涨幅较大，Edesa Biotech, Inc.、Onconetix, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为306.82%、199.87%、139.79%，振幅较大的相关个股有Edesa Biotech, Inc.、Onconetix, Inc.、Yd Bio Ltd C/Wts 28/08/2030，振幅分别为76.32%、47.82%、43.99%。Maplight Therapeutics, Inc.公司简介：malight Therapeutics是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304034115a447d7f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304034115a447d7f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","BK4007","LENZ","MPLT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}